keyword
MENU ▼
Read by QxMD icon Read
search

Derek yellon

keyword
https://www.readbyqxmd.com/read/27894068/residual-myocardial-iron-following-intramyocardial-hemorrhage-during-the-convalescent-phase-of-reperfused-st-segment-elevation-myocardial-infarction-and-adverse-left-ventricular-remodeling
#1
Heerajnarain Bulluck, Stefania Rosmini, Amna Abdel-Gadir, Steven K White, Anish N Bhuva, Thomas A Treibel, Marianna Fontana, Manish Ramlall, Ashraf Hamarneh, Alex Sirker, Anna S Herrey, Charlotte Manisty, Derek M Yellon, Peter Kellman, James C Moon, Derek J Hausenloy
BACKGROUND: The presence of intramyocardial hemorrhage (IMH) in ST-segment-elevation myocardial infarction patients reperfused by primary percutaneous coronary intervention has been associated with residual myocardial iron at follow-up, and its impact on adverse left ventricular (LV) remodeling is incompletely understood and is investigated here. METHODS AND RESULTS: Forty-eight ST-segment-elevation myocardial infarction patients underwent cardiovascular magnetic resonance at 4±2 days post primary percutaneous coronary intervention, of whom 40 had a follow-up scan at 5±2 months...
October 2016: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/27865185/a-new-era-in-the-management-of-type-2-diabetes-is-cardioprotection-at-long-last-a-reality
#2
EDITORIAL
Xavier Rossello, Derek M Yellon
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit...
November 12, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27796607/exosomes-and-cardiovascular-protection
#3
Sean M Davidson, Kaloyan Takov, Derek M Yellon
Most, if not all, cells of the cardiovascular system secrete small, lipid bilayer vesicles called exosomes. Despite technical challenges in their purification and analysis, exosomes from various sources have been shown to be powerfully cardioprotective. Indeed, it is possible that much of the so-called "paracrine" benefit in cardiovascular function obtained by stem cell therapy can be replicated by the injection of exosomes produced by stem cells. However, exosomes purified from plasma appear to be just as capable of activating cardioprotective pathways...
October 29, 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/27766474/ischaemic-conditioning-and-targeting-reperfusion-injury-a-30%C3%A2-year-voyage-of-discovery
#4
REVIEW
Derek J Hausenloy, Jose A Barrabes, Hans Erik Bøtker, Sean M Davidson, Fabio Di Lisa, James Downey, Thomas Engstrom, Péter Ferdinandy, Hector A Carbrera-Fuentes, Gerd Heusch, Borja Ibanez, Efstathios K Iliodromitis, Javier Inserte, Robert Jennings, Neena Kalia, Rajesh Kharbanda, Sandrine Lecour, Michael Marber, Tetsuji Miura, Michel Ovize, Miguel A Perez-Pinzon, Hans Michael Piper, Karin Przyklenk, Michael Rahbek Schmidt, Andrew Redington, Marisol Ruiz-Meana, Gemma Vilahur, Jakob Vinten-Johansen, Derek M Yellon, David Garcia-Dorado
To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research...
November 2016: Basic Research in Cardiology
https://www.readbyqxmd.com/read/27743118/from-basic-mechanisms-to-clinical-applications-in-heart-protection-new-players-in-cardiovascular-diseases-and-cardiac-theranostics-meeting-report-from-the-third-international-symposium-on-new-frontiers-in-cardiovascular-research
#5
REVIEW
Hector A Cabrera-Fuentes, Julian Aragones, Jürgen Bernhagen, Andreas Boening, William A Boisvert, Hans E Bøtker, Heerajnarain Bulluck, Stuart Cook, Fabio Di Lisa, Felix B Engel, Bernd Engelmann, Fulvia Ferrazzi, Péter Ferdinandy, Alan Fong, Ingrid Fleming, Erich Gnaiger, Sauri Hernández-Reséndiz, Siavash Beikoghli Kalkhoran, Moo Hyun Kim, Sandrine Lecour, Elisa A Liehn, Michael S Marber, Manuel Mayr, Tetsuji Miura, Sang-Bing Ong, Karlheinz Peter, Daniel Sedding, Manvendra K Singh, M Saadeh Suleiman, Hans J Schnittler, Rainer Schulz, Winston Shim, Daniel Tello, Carl-Wilhelm Vogel, Malcolm Walker, Qilong Oscar Yang Li, Derek M Yellon, Derek J Hausenloy, Klaus T Preissner
In this meeting report, particularly addressing the topic of protection of the cardiovascular system from ischemia/reperfusion injury, highlights are presented that relate to conditioning strategies of the heart with respect to molecular mechanisms and outcome in patients' cohorts, the influence of co-morbidities and medications, as well as the contribution of innate immune reactions in cardioprotection. Moreover, developmental or systems biology approaches bear great potential in systematically uncovering unexpected components involved in ischemia-reperfusion injury or heart regeneration...
November 2016: Basic Research in Cardiology
https://www.readbyqxmd.com/read/27550967/cardioprotection-the-disconnect-between-bench-and-bedside
#6
Xavier Rossello, Derek M Yellon
No abstract text is available yet for this article.
August 23, 2016: Circulation
https://www.readbyqxmd.com/read/27402229/automated-extracellular-volume-fraction-mapping-provides-insights-into-the-pathophysiology-of-left-ventricular-remodeling-post-reperfused-st-elevation-myocardial-infarction
#7
Heerajnarain Bulluck, Stefania Rosmini, Amna Abdel-Gadir, Steven K White, Anish N Bhuva, Thomas A Treibel, Marianna Fontana, Esther Gonzalez-Lopez, Patricia Reant, Manish Ramlall, Ashraf Hamarneh, Alex Sirker, Anna S Herrey, Charlotte Manisty, Derek M Yellon, Peter Kellman, James C Moon, Derek J Hausenloy
BACKGROUND: Whether the remote myocardium of reperfused ST-segment elevation myocardial infarction (STEMI) patients plays a part in adverse left ventricular (LV) remodeling remains unclear. We aimed to use automated extracellular volume fraction (ECV) mapping to investigate whether changes in the ECV of the remote (ECVR emote) and infarcted myocardium (ECVI nfarct) impacted LV remodeling. METHODS AND RESULTS: Forty-eight of 50 prospectively recruited reperfused STEMI patients completed a cardiovascular magnetic resonance at 4±2 days and 40 had a follow-up scan at 5±2 months...
July 2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27379920/a-critical-review-on-the-translational-journey-of-cardioprotective-therapies
#8
REVIEW
Xavier Rossello, Derek M Yellon
The failure to translate novel cardioprotective therapies tested in pre-clinical studies into the clinical setting for patient benefit can be attributed to a number of factors at different stages of the research process. This review focuses on the evidences and the gaps with regard to the translational journey of cardioprotective interventions. Gaps are classified into 3 main groups: 1) those related to pre-clinical studies, 2) those associated with the validation of infarct size as a good surrogate and 3) those based on design and interpretation of randomized clinical trials on cardioprotection...
October 1, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27338249/co-dependence-of-the-neural-and-humoral-pathways-in-the-mechanism-of-remote-ischemic-conditioning
#9
Jack M J Pickard, Sean M Davidson, Derek J Hausenloy, Derek M Yellon
The cardioprotection afforded by remote ischaemic conditioning (RIC) is mediated via a complex mechanism involving sensory afferent nerves, the vagus nerve, and release of a humoral blood-borne factor. However, it is unknown whether release of the protective factor depends on vagal activation or occurs independently. This study aimed to evaluate the co-dependence of the neural and humoral pathways of RIC, focussing on the vagus nerve and intrinsic cardiac ganglia. In the first study, anesthetised rats received bilateral cervical vagotomy or sham-surgery immediately prior to RIC (4 × 5 min limb ischemia-reperfusion) or sham-RIC...
July 2016: Basic Research in Cardiology
https://www.readbyqxmd.com/read/27335054/exogenous-administration-of-recombinant-mif-at-physiological-concentrations-failed-to-attenuate-infarct-size-in-a-langendorff-perfused-isolated-mouse-heart-model
#10
Xavier Rossello, Niall Burke, Christian Stoppe, Jurgen Bernhagen, Sean M Davidson, Derek M Yellon
PURPOSE: Evidence suggests a two-pronged role of endogenous macrophage migration inhibitory factor (MIF) release in ischemia/reperfusion injury. We aimed to assess whether its exogenous administration confers cardioprotection. METHODS: Male C57/BL6 mice were randomly allocated to receive recombinant mouse MIF (rMIF) at physiological (ng/mL) concentrations in a dose-response fashion before or after a protocol of 35 min of ischemia and 2 h of reperfusion in an isolated Langendorff-perfused model with infarct size as endpoint...
June 22, 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/27118196/targeting-reperfusion-injury-in-patients-with-st-segment-elevation-myocardial-infarction-trials-and-tribulations
#11
Derek J Hausenloy, Hans Erik Botker, Thomas Engstrom, David Erlinge, Gerd Heusch, Borja Ibanez, Robert A Kloner, Michel Ovize, Derek M Yellon, David Garcia-Dorado
No abstract text is available yet for this article.
April 26, 2016: European Heart Journal
https://www.readbyqxmd.com/read/26926269/quantifying-the-area-at-risk-in-reperfused-st-segment-elevation-myocardial-infarction-patients-using-hybrid-cardiac-positron-emission-tomography-magnetic-resonance-imaging
#12
Heerajnarain Bulluck, Steven K White, Georg M Fröhlich, Steven G Casson, Celia O'Meara, Ayla Newton, Jennifer Nicholas, Peter Weale, Simon M Y Wan, Alex Sirker, James C Moon, Derek M Yellon, Ashley Groves, Leon Menezes, Derek J Hausenloy
BACKGROUND: Hybrid positron emission tomography and magnetic resonance allows the advantages of magnetic resonance in tissue characterizing the myocardium to be combined with the unique metabolic insights of positron emission tomography. We hypothesized that the area of reduced myocardial glucose uptake would closely match the area at risk delineated by T2 mapping in ST-segment-elevation myocardial infarction patients. METHODS AND RESULTS: Hybrid positron emission tomography and magnetic resonance using (18)F-fluorodeoxyglucose (FDG) for glucose uptake was performed in 21 ST-segment-elevation myocardial infarction patients at a median of 5 days...
March 2016: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/26859232/promising-strategies-to-minimize-reperfusion-injury-in-stemi
#13
Heerajnarain Bulluck, Robert L Yellon, Derek M Yellon
Morbidity in patients presenting with acute ST-segment elevation myocardial infarction remains significant despite prompt reperfusion by primary percutaneous coronary intervention. This has been partly attributed to "myocardial reperfusion injury" whereby the process of restoring coronary blood flow paradoxically induces myocardial injury and cardiomyocyte death, mitigating the full beneficial effects of reperfusion. A large number of cardioprotective therapies to reduce myocardial infarct size have been investigated in preclinical and small proof-of-concept clinical studies with mixed results...
June 2016: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/26843289/ischaemic-conditioning-and-reperfusion-injury
#14
REVIEW
Derek J Hausenloy, Derek M Yellon
The 30-year anniversary of the discovery of 'ischaemic preconditioning' is in 2016. This endogenous phenomenon can paradoxically protect the heart from acute myocardial infarction by subjecting it to one or more brief cycles of ischaemia and reperfusion. Apart from complete reperfusion, this method is the most powerful intervention known for reducing infarct size. The concept of ischaemic preconditioning has evolved into 'ischaemic conditioning', a term that encompasses a number of related endogenous cardioprotective strategies, applied either directly to the heart (ischaemic preconditioning or postconditioning) or from afar, for example a limb (remote ischaemic preconditioning, perconditioning, or postconditioning)...
April 2016: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/26807534/effect-of-remote-ischaemic-conditioning-in-oncology-patients-undergoing-chemotherapy-rationale-and-design-of-the-eric-onc-study-a-single-center-blinded-randomized-controlled-trial
#15
Robin Chung, Angshuman Maulik, Ashraf Hamarneh, Daniel Hochhauser, Derek J Hausenloy, J Malcolm Walker, Derek M Yellon
Cancer survival continues to improve, and thus cardiovascular consequences of chemotherapy are increasingly important determinants of long-term morbidity and mortality. Conventional strategies to protect the heart from chemotherapy have important hemodynamic or myelosuppressive side effects. Remote ischemic conditioning (RIC) using intermittent limb ischemia-reperfusion reduces myocardial injury in the setting of percutaneous coronary intervention. Anthracycline cardiotoxicity and ischemia-reperfusion injury share common biochemical pathways in cardiomyocytes...
February 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/26780906/cangrelor-mediated-cardioprotection-requires-platelets-and-sphingosine-phosphorylation
#16
Michael V Cohen, Xi-Ming Yang, James White, Derek M Yellon, Robert M Bell, James M Downey
In animal models platelet P2Y12 receptor antagonists put the heart into a protected state, not as a result of suppressed thrombosis but rather through protective signaling, similar to that for ischemic postconditioning. While both ischemic postconditioning and the P2Y12 blocker cangrelor protect blood-perfused hearts, only the former protects buffer-perfused hearts indicating that the blocker requires a blood-borne constituent or factor to protect. We used an anti-platelet antibody to make thrombocytopenic rats to test if that factor resides within the platelet...
April 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/26743452/microvesicles-and-exosomes-new-players-in-metabolic-and-cardiovascular-disease
#17
REVIEW
Charlotte Lawson, Jose M Vicencio, Derek M Yellon, Sean M Davidson
The past decade has witnessed an exponential increase in the number of publications referring to extracellular vesicles (EVs). For many years considered to be extracellular debris, EVs are now seen as novel mediators of endocrine signalling via cell-to-cell communication. With the capability of transferring proteins and nucleic acids from one cell to another, they have become an attractive focus of research for different pathological settings and are now regarded as both mediators and biomarkers of disease including cardio-metabolic disease...
February 2016: Journal of Endocrinology
https://www.readbyqxmd.com/read/26674987/reducing-myocardial-infarct-size-challenges-and-future-opportunities
#18
REVIEW
Heerajnarain Bulluck, Derek M Yellon, Derek J Hausenloy
Despite prompt reperfusion by primary percutaneous coronary intervention (PPCI), the mortality and morbidity of patients presenting with an acute ST-segment elevation myocardial infarction (STEMI) remain significant with 9% death and 10% heart failure at 1 year. In these patients, one important neglected therapeutic target is 'myocardial reperfusion injury', a term given to the cardiomyocyte death and microvascular dysfunction which occurs on reperfusing ischaemic myocardium. A number of cardioprotective therapies (both mechanical and pharmacological), which are known to target myocardial reperfusion injury, have been shown to reduce myocardial infarct (MI) size in small proof-of-concept clinical studies-however, being able to demonstrate improved clinical outcomes has been elusive...
March 2016: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/26667317/meeting-report-from-the-2nd-international-symposium-on-new-frontiers-in-cardiovascular-research-protecting-the-cardiovascular-system-from-ischemia-between-bench-and-bedside
#19
Hector A Cabrera-Fuentes, Corina Alba-Alba, Julian Aragones, Jürgen Bernhagen, William A Boisvert, Hans E Bøtker, Gabriela Cesarman-Maus, Ingrid Fleming, David Garcia-Dorado, Sandrine Lecour, Elisa Liehn, Michael S Marber, Nephtali Marina, Manuel Mayr, Oscar Perez-Mendez, Tetsuji Miura, Marisol Ruiz-Meana, Eduardo M Salinas-Estefanon, Sang-Bing Ong, Hans J Schnittler, Jose T Sanchez-Vega, Adriana Sumoza-Toledo, Carl-Wilhelm Vogel, Dina Yarullina, Derek M Yellon, Klaus T Preissner, Derek J Hausenloy
Recent advances in basic cardiovascular research as well as their translation into the clinical situation were the focus at the last "New Frontiers in Cardiovascular Research meeting". Major topics included the characterization of new targets and procedures in cardioprotection, deciphering new players and inflammatory mechanisms in ischemic heart disease as well as uncovering microRNAs and other biomarkers as versatile and possibly causal factors in cardiovascular pathogenesis. Although a number of pathological situations such as ischemia-reperfusion injury or atherosclerosis can be simulated and manipulated in diverse animal models, also to challenge new drugs for intervention, patient studies are the ultimate litmus test to obtain unequivocal information about the validity of biomedical concepts and their application in the clinics...
January 2016: Basic Research in Cardiology
https://www.readbyqxmd.com/read/26661194/immediate-remote-ischemic-postconditioning-after-hypoxia-ischemia-in-piglets-protects-cerebral-white-matter-but-not-grey-matter
#20
Mojgan Ezzati, Alan Bainbridge, Kevin D Broad, Go Kawano, Aaron Oliver-Taylor, Eridan Rocha-Ferreira, Daniel Alonso-Alconada, Igor Fierens, Jamshid Rostami, K Jane Hassell, Ilias Tachtsidis, Pierre Gressens, Mariya Hristova, Kate Bennett, Sophie Lebon, Bobbi Fleiss, Derek Yellon, Derek J Hausenloy, Xavier Golay, Nicola J Robertson
Remote ischemic postconditioning (RIPostC) is a promising therapeutic intervention whereby brief episodes of ischemia/reperfusion of one organ (limb) mitigate damage in another organ (brain) that has experienced severe hypoxia-ischemia. Our aim was to assess whether RIPostC is protective following cerebral hypoxia-ischemia in a piglet model of neonatal encephalopathy (NE) using magnetic resonance spectroscopy (MRS) biomarkers and immunohistochemistry. After hypoxia-ischemia (HI), 16 Large White female newborn piglets were randomized to: (i) no intervention (n = 8); (ii) RIPostC - with four, 10-min cycles of bilateral lower limb ischemia/reperfusion immediately after HI (n = 8)...
August 2016: Journal of Cerebral Blood Flow and Metabolism
keyword
keyword
108101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"